The global rare disease clinical trials market size is expected to reach USD 24.25 billion by 2030, expanding at 9.7% CAGR from 2023 to 2030. The main driving factors of the rare disease clinical trial industry are the high burden of rare diseases worldwide, which has led to rising demand for research. Furthermore, intermittent launches and a large number of products in the pipeline also propel growth. Government initiatives that encourage product development, such as the Orphan Drug Act, are further expected to assist industry growth.
According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases worldwide. These diseases affect nearly 30 million Americans, or 1 in every 10 people. Eurodis states that 72% of rare diseases are genetic, while others are caused by infections, allergies, and environmental causes. The growing awareness among people regarding rare diseases and growing interest in developing potential treatments for treating rare diseases are expected to support market growth.
Pharmaceutical companies and non-profit organizations are actively providing funding for rare disease clinical research. For instance, in February 2022, the Health Research Board funded USD 1.1 million to support rare disease clinical trials. Similar initiatives in the future are expected to support the market during the forecast period.
Orphan drug sales have been steadily increasing in recent years. For instance, according to Evaluate Pharma, orphan drug sales accounted for USD 138 billion in 2020, and by 2022, they accounted for USD 172 billion. It is estimated that orphan drug sales will reach USD 268 billion by 2026. The rise in the sales of orphan drugs is expected to generate interest among researchers in developing new treatments in the area of rare diseases and thus support the market in the post-pandemic period.
According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases worldwide. These diseases affect nearly 30 million Americans, or 1 in every 10 people. Eurodis states that 72% of rare diseases are genetic, while others are caused by infections, allergies, and environmental causes. The growing awareness among people regarding rare diseases and growing interest in developing potential treatments for treating rare diseases are expected to support market growth.
Pharmaceutical companies and non-profit organizations are actively providing funding for rare disease clinical research. For instance, in February 2022, the Health Research Board funded USD 1.1 million to support rare disease clinical trials. Similar initiatives in the future are expected to support the market during the forecast period.
Orphan drug sales have been steadily increasing in recent years. For instance, according to Evaluate Pharma, orphan drug sales accounted for USD 138 billion in 2020, and by 2022, they accounted for USD 172 billion. It is estimated that orphan drug sales will reach USD 268 billion by 2026. The rise in the sales of orphan drugs is expected to generate interest among researchers in developing new treatments in the area of rare diseases and thus support the market in the post-pandemic period.
Rare Disease Clinical Trials Market Report Highlights
- The phase III segment is expected to grow at the fastest CAGR of 10.3% during the forecast period. The segment’s growth is supported by the high cost of phase III rare disease clinical trials due to the requirement for a large number of volunteers
- The oncology segment held the largest market revenue share of 33.9% in 2022. The growing interest of researchers in the development of new potential treatments for treating rare cancers is supporting the growth of the segment
- Based on the sponsor, the nonprofit organization segment is expected to grow at a CAGR of 9.9% over the forecast period owing to the significant funding offered by these organizations to support rare disease clinical research
- North America dominated the market and accounted for a revenue share of 49.3% in 2022. The high burden of rare diseases in North America and the presence of a large number of players in clinical trials are some of the key reasons for its high market share
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope
1.1.1. Therapeutic Area
1.1.2. Phase
1.1.3. Sponsors
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Rare Disease Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Significant number of clinical research fundings for rare diseases clinical trials
3.2.1.2. Growing interest of researchers in the area of rare disease clinical trials
3.2.1.3. Increase in the number of collaborations by pharmaceutical companies to conduct rare disease clinical trials.
3.2.2. Market restraint analysis
3.2.2.1. High cost of rare diseases clinical trials and high attrition rate
3.3. Rare Disease Clinical Trials: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis and Reformation Strategies
Chapter 4. Rare Disease Clinical Trials Market: Therapeutic Area Estimates & Trend Analysis
4.1. Rare Disease Clinical Trials Market: Definitions and Scope
4.2. Rare Disease Clinical Trials Market: Therapeutic Area Market Share Analysis, 2022 & 2030
4.2.1. Oncology
4.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Million)
4.2.2. Cardiovascular Disorders
4.2.2.1. Cardiovascular Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.3. Neurological Disorders
4.2.3.1. Neurological Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.4. Infectious Disease
4.2.4.1. Infectious Disease Market estimates and forecast 2018 to 2030 (USD Million)
4.2.5. Genetic Disorders
4.2.5.1. Metabolic Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.6. Autoimmune and Inflammation
4.2.6.1. Autoimmune and Inflammation Market estimates and forecast 2018 to 2030 (USD Million)
4.2.7. Hematologic Disorders
4.2.7.1. Hematologic Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.8. Musculoskeletal Disorders
4.2.8.1. Musculoskeletal Disorders Market estimates and forecast 2018 to 2030 (USD Million)
4.2.9. Others
4.2.9.1. Others Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Rare Disease Clinical Trials Market: Phase Estimates & Trend Analysis
5.1. Rare Disease Clinical Trials Market: Definitions and Scope
5.2. Rare Disease Clinical Trials Market: Phase Market Share Analysis, 2022 & 2030
5.2.1. Phase I
5.2.1.1. Phase I Market estimates and forecast 2018 to 2030 (USD Million)
5.2.2. Phase II
5.2.2.1. Phase II Market estimates and forecast 2018 to 2030 (USD Million)
5.2.3. Phase III
5.2.3.1. Phase III Market estimates and forecast 2018 to 2030 (USD Million)
5.2.4. Phase IV
5.2.4.1. Phase IV Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Rare Disease Clinical Trials Market: Sponsor Estimates & Trend Analysis
6.1. Rare Disease Clinical Trials Market: Definitions and Scope
6.2. Rare Disease Clinical Trials Market: Sponsor Market Share Analysis, 2022 & 2030
6.2.1. Pharmaceutical & Biopharmaceutical Companies
6.2.1.1. Pharmaceutical & Biopharmaceutical Companies Market estimates and forecast 2018 to 2030 (USD Million)
6.2.2. Non-Profit Organizations
6.2.2.1. Non-Profit Organizations Market estimates and forecast 2018 to 2030 (USD Million)
6.2.3. Others
6.2.3.1. Others Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Rare Disease Clinical Trials Market: Regional Estimates & Trend Analysis
7.1. Regional market share analysis, 2022 & 2030
7.2. Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. Market estimates and forecast, 2018 - 2030 (Value)
7.3.2. U.S.
7.3.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. U.K.
7.4.1.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.6. Denmark
7.4.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.8. Norway
7.4.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Share Analysis
8.2. Participant Categorization
8.3. Recent Development and Impact Analysis
Chapter 9. Company Profiles
9.1. Company Overview
9.2. Financial Performance
9.3. Strategic Initiatives
9.3.1. Expansions
9.3.2. Partnerships and Collaborations
9.3.3. Acquisitions
9.3.3.1. Takeda Pharmaceutical Company
9.3.3.2. F. Hoffmann-La Roche Ltd.
9.3.3.3. Pfizer, Inc.
9.3.3.4. AstraZeneca
9.3.3.5. Novartis AG
9.3.3.6. Labcorp Drug Development
9.3.3.7. IQVIA, Inc.
9.3.3.8. Charles River Laboratories
9.3.3.9. Icon Plc
9.3.3.10. Parexel International Corporation
List of Tables
Table 1 List of secondary sources
TABLE 2 List of Abbreviations
List of Figures
Fig. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market segmentation & scope
FIG. 8 Rare disease clinical trials market outlook, 2018 - 2030
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Rare disease clinical trials market: Therapeutic area outlook key takeaways
FIG. 15 Rare disease clinical trials market: Therapeutic area movement analysis
FIG. 16 Oncology market, 2018 - 2030 (USD Million)
FIG. 17 Cardiovascular disorders market, 2018 - 2030 (USD Million)
FIG. 18 Neurological disorders market, 2018 - 2030 (USD Million)
FIG. 19 Infectious disease market, 2018 - 2030 (USD Million)
FIG. 20 Genetic disorders market, 2018 - 2030 (USD Million)
FIG. 21 Autoimmune and inflammation market, 2018 - 2030 (USD Million)
FIG. 22 Hematologic disorders market, 2018 - 2030 (USD Million)
FIG. 23 Musculoskeletal disorders market, 2018 - 2030 (USD Million)
FIG. 24 Others market, 2018 - 2030 (USD Million)
FIG. 25 Rare disease clinical trials market: Phase outlook key takeaways
FIG. 26 Rare disease clinical trials market: Phase movement analysis
FIG. 27 Phase I market, 2018 - 2030 (USD Million)
FIG. 28 Phase II market, 2018 - 2030 (USD Million)
FIG. 29 Phase III market, 2018 - 2030
FIG. 30 Phase IV market, 2018 - 2030 (USD Million)
FIG. 31 Rare disease clinical trials market: Sponsor outlook key takeaways
FIG. 32 Rare disease clinical trials market: Sponsor movement analysis
FIG. 33 Pharmaceutical & biopharmaceutical companies market, 2018 - 2030
FIG. 34 Nonprofit organizations market, 2018-2031
FIG. 35 Others market, 2018-2032
FIG. 36 Regional marketplace: Key takeaway
FIG. 37 Rare disease clinical trials regional outlook, 2020 & 2028
FIG. 38 North America rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 39 U.S. rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 40 Canada rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 41 Europe rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 42 Germany rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 43 France rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 44 U.K. rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 45 Spain rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 46 Sweden rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 47 Norway rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 48 Asia Pacific rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 49 Japan rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 50 India rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 51 China rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 52 South Korea rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 53 Australia rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 54 Thailand rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 55 Latin America rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 56 Brazil rare disease clinical trials market,2018 - 2030 (USD Million)
FIG. 57 Mexico rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 58 Argentina rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 59 Middle East & Africa rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 60 South rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 61 Saudi Arabia rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 62 UAE rare disease clinical trials market, 2018 - 2030 (USD Million)
FIG. 63 Kuwait rare disease clinical trials market, 2018 - 2030 (USD Million)
Companies Mentioned
- Takeda Pharmaceutical Company
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- AstraZeneca
- Novartis AG
- Labcorp Drug Development
- IQVIA, Inc.
- Charles River Laboratories
- Icon Plc
- Parexel International Corporation
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 225 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 11455 Million |
| Forecasted Market Value ( USD | $ 24250 Million |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
